Efficacy and safety of a fixed-dose combination of dapagliflozin and linagliptin (AJU-A51) in patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, parallel-group, placebo-controlled phase III study.

Farxiga (dapagliflozin) - Ono Pharma, AstraZeneca

AJU-A51 - AJU Pharm

Tradjenta (linagliptin) - Boehringer Ingelheim, Eli Lilly

http://www.ncbi.nlm.nih.gov/pubmed/39375869

Bon Jeong Ku; Byung-Wan Lee; Chang Beom Lee; Ho Sang Shon; Jae Hyeon Kim; Jong Chul Won; Joong-Yeol Park; Jun Goo Kang; Jun Hwa Hong; Jung Hwan Park; Kyung Wan Min; Myung Jin Kim; Sang Yong Kim; Tae Nyun Kim; Woo Je Lee

Oct 8, 2024